innovating eyecare through collaborative research
Your Partners in Research
The CUREOS Clinical Research Network works collaboratively and supports clinicians around the world to develop and conduct high quality research to improve quality of life and reduce treatment burdens.
We are a passionate and experienced team that work collaboratively to support clinicians and product development teams through high quality research trials, site management and medical writing.
Our research sites are currently located in NSW, Queensland, Victoria, South Australia and Tasmania; with growth planned to establish trial sites in Western Australia, ACT and regional Australia.
Participants
If you are interested in participating in a research trial, please click below to find out more and get in touch with us.
Clinicians
If you have a patient that you’d like to refer for a clinical trial, or you’d like to hear more about this, feel free to click below or contact us for more information.
Collaborators
We are looking to expand our research network. If you are intersted in working with us or would like to find out more, please contact us below.
What we do
Clinical trials
We are currently running a wide range of clinical trials for geographic atrophy, neovascular AMD, Diabetes, retinal vein occlusions and many others.
Research services
The CUREOS team is experienced in clinical trials, site management and medical writing…
Research publications
Our team of medical writers have developed and contributed to numerous research publications…
Keep up to date here
Trial Spotlight for Wet AMD
We are currently looking for patients who have been newly diagnosed with wet/neovascular AMD, and not received any injections in that eye. This trial is
Kriya Therapeutics Presents Preclinical Data for KRIYA-825 Gene Therapy in Geographic Atrophy
Kriya Therapeutics announce promising pre-clinical results for KRIYA-825, a single gene therapy delivered via suprachoroidal injection for the treatment of geographic atrophy (GA). KRIYA-825
High Dose Eylea (8mg) approved in China for Wet Age-Related Macular Degeneration
The approval of Eylea 8 mg (aflibercept 8 mg) in China for the treatment of wet age-related macular degeneration (AMD) comes following the positive results
